Emergent BioSolutions Inc. (EBS) earnings date
Mar 1, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 12 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 2, 2026 | after close | 33 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 36 | 8-K |
| Q1 FY2026 | Thu, Apr 30, 2026 | after close | 30 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Wed, Oct 29, 2025 | after close | 29 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | after close | 37 | 8-K |
| Q4 FY2024 | Mon, Mar 3, 2025 | after close | 62 | 8-K |
What they guided beta
| Q3 FY2026 | "The decrease was primarily attributable to lower sales of OTC NARCAN ® , mostly driven by an unfavorable price-volume mix in U.S. public interest channels, partially mitigated by increases in Canadian sales of branded NARCAN ® . 2 Anthrax MCM For Q3 2026, revenues from Anthrax MCM products increased $23.7 million as compared with Q3 2025." exhibit |
| Q3 FY2026 | "The increase was partially offset by lower marketing and administrative support expenses. 3 ADDITIONAL FINANCIAL INFORMATION (1) Capital Expenditures ($ in millions) Q3 2026 Q3 2025 % Change Capital expenditures $ 3.3 $ 3.4 (3) % Capital expenditures as a % of total revenues 3 % 1 % For Q3 2026, capital expenditures decreased slightly due to reduced development activities across the Company’s facilities. 4 REPORTABLE SEGMENT INFORMATION The Company manages the business with a focus on three operating segments: (1) a Commercial Products segment consisting of NARCAN ® Nasal Spray and KLOXXADO ® " exhibit |
| Q3 FY2026 | "MCM Product segment adjusted gross margin in the current year period excludes the impacts of intangible asset amortization of $22.6 million, inventory step-up provision of $2.4 million, the portion of stock-based compensation expense recorded as cost of sales of $1.9 million and severance and restructuring costs of $1.3 million. 8 2026 FINANCIAL FORECAST The Company provides the following updated financial forecast for full year 2026, reflecting management's expectations based on the most current information available." exhibit |
| Q3 FY2026 | "The updated ranges for our 2026 forecast reflect this adjustment." exhibit |
| Q2 FY2026 | "Restructuring business operations to align resourcing to current needs; expected to result in annualized savings of approximately $40 million when fully implemented GAITHERSBURG, Md., August 5, 2026 —Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2026." exhibit |
| Q2 FY2026 | "“Emergent delivered a strong second quarter, significantly exceeding the high end of our guidance range with revenues of $234 million, primarily driven by accelerated MCM/biodefense contract modifications secured with the U.S. government." exhibit |
| Q2 FY2026 | "The increase was primarily due higher KLOXXADO ® sales and Canadian sales of branded NARCAN ® , largely offset by lower sales volumes of OTC NARCAN ® in the U.S. Commercial Products gross margin decreased $19.7 million, or 60%, to $13.3 million for the six months ended June 30, 2026." exhibit |
| Q2 FY2026 | "MCM Product segment adjusted gross margin in the current year period excludes the impacts of intangible asset amortization of $14.8 million, the portion of stock-based compensation expense recorded as cost of sales of $1.2 million and inventory step-up provision of $0.3 million. 8 2026 FINANCIAL FORECAST The Company provides the following updated financial forecast for full year 2026, reflecting management's expectations based on the most current information available." exhibit |
| Q2 FY2026 | "METRIC ($ in millions ) Updated Range (as of 08/05/2026) Action Previous Range (as of 04/30/2026) Total revenues $645 - $675 REVISED $720 - $760 Net loss $(245) - $(225) REVISED $(30) - $(10) Adjusted net income (2) $10 - $30 REVISED $45 - $65 Adjusted EBITDA (2) $130 - $150 REVISED $155 - $175 Adjusted gross margin % (2) 42% - 44% REVISED 45% - 47% Key Assumptions ($ and shares in millions) Updated Range (as of 08/05/2026) Interest expense ~$40 R&D ~6% of Revenues SG&A ~27% to 28% of Revenues Weighted avg. fully diluted share count ~52 Stock-based compensation expense ~$19 Capex ~$17 Deprecia" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/EBS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/EBS
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/EBS/"><img src="https://veritasdata.dev/embed/EBS.svg" alt="EBS earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/EBS/)
Script
<script async src="https://veritasdata.dev/embed/EBS.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/EBS"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.